CHRONIC MYELOGENOUS LEUKEMIA IN BLAST CRISIS TREATED WITH TRIAZOFURIN

这是一项评估新的抗白血病药物能力的二期研究。 噻唑呋喃类药物，用于诱导慢性粒细胞白血病患者的血液系统缓解 慢性粒细胞白血病处于急变期。两国之间的关系 将检查生化和血液学影响以及毒性 将对个人资料进行评估。我们将研究生化和生物化学之间的关系 将对每日血液样本和每周骨髓样本进行参数评估 吸气。后续整合周期将管理到 有反应的病人。

This is a phase II study to evaluation the capacity of new antileukemic agent, tiazofurin, to induce hematologic remissions in patients with chronic myelogenous leukemia in blast crisis. The relationship between the biochemical and hematologic effects will be examined and the toxicity profile will be assessed. We will examine relationship between biochemical parameters will be assessed on daily blood samples and weekly bone marrow aspirates. Subsequent consolidation cycles will be administered to responding patients.